ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Uncovering the gastroprotective properties of araucaria brown propolis and its active compound, abietic acid.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although Araucaria brown propolis is a singular propolis with potential therapeutic applications, its anti-ulcer activity remains unexplored. This study investigated the gastroprotective effects of Araucaria brown propolis hydroalcoholic extract (HeBPA, 30- 300 mg/kg and its isolated compound, abietic acid (AA) in corresponding doses to its content in HEBPA. The extract's anti-ulcer activity was evaluated using acidified ethanol-induced gastric ulcers and pylorus ligation to assess gastric antisecretory activity. Additionally, the study examined histological, oxidative, and inflammatory parameters, and the extract's anti-Helicobacter pylori and cytotoxic effects. The 100 mg/kg oral dose of HeBPA promoted gastroprotection by 69.63% by increasing antioxidant defenses (GSH, CAT, and SOD) and reducing MPO activity and MDA levels in ulcerated mucosa. This gastroprotective effect was not due to antisecretory activity, but rather involved non-protein sulfhydryl compounds, alpha-2 adrenergic receptors, prostaglandins, and nitric oxide, as evidenced by the abolition of the effect with L-NAME, NEM, indomethacin, or yohimbine pre-treatment. HeBPA increased mucin stained by PAS in the gastric mucosa and prevented histological damage, reducing edema and inflammatory infiltrate. Additionally, HeBPA promoted fibroblast proliferation at 1 µg/mL, but showed no antibacterial activity against H. pylori (MIC > 1000 µg/mL). In addition, AA at 17 mg/kg reduced by 44.82% the ethanol induced- ulcers. These findings contribute to validate the anti-ulcer effect of Brazilian Araucaria brown propolis, highlighting its potential as a natural resource for developing new gastric ulcer treatments. Notably, AA does appear to be a key bioactive compound responsible for this effect.
Indexed as
Identifiers
41020946What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.